Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Tesla Raises Cybertruck Prices by $5,000 in US 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Add as a preferred source on Google
MENLO PARK, Calif., May 01, 2018 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present an overview of the company at the Deutsche Bank 43rd Annual Healthcare Conference.
- Location: Boston, MA
- Presentation date: Tuesday, May 8, 2018
- Presentation time: 2:50 p.m. ET
A live audio webcast and archive of the presentation will be available at http://investor.dermira.com.
About Dermira
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s pipeline includes two late-stage product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate (formerly DRM04), for which a New Drug Application is under review by the U.S. Food and Drug Administration for the treatment of primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed for normal body temperature regulation), and lebrikizumab, in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. Dermira is headquartered in Menlo Park, Calif. For more information, please visit http://www.dermira.com. Follow @DermiraInc on Twitter and LinkedIn.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com), LinkedIn page (https://www.linkedin.com/company/dermira-inc-) and corporate Twitter account (@DermiraInc) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website, LinkedIn page and Twitter account in addition to following its SEC filings, press releases, public conference calls and webcasts.
Contacts:
Media:
Erica Jefferson
Vice President, Corporate Communications
650-421-7216
[email protected]
Investors:
Ian Clements, Ph.D.
Vice President, Investor Relations
650-422-7753
[email protected]
Robert H. Uhl
Westwicke Partners
Managing Director
858-356-5932
[email protected]
